Selected Publications

 

LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DR, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 337(8750):1124-5, 5/1991.

 

Murray JL, Wilmanns CW, Mujoo K, Janus MA, Rosenblum MG. Factors influencing in vivo localization of radiolabeled anti-melanoma monoclonal antibody combinations compared to single antibodies. Antibody Immunoconjugates and Radiopharmaceuticals 5(2):209-225, 1992.

 

Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McManni JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 9(6):364-72, 6/2003.

 

Liu Y, Cheung LH, Thorpe P, Rosenblum MG. Mechanistic studies of a novel human fusion toxin    composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. Mol Cancer Ther 2(10):949-59, 10/2003.

 

Liu Y, Cheung LH, Marks JW, Rosenblum MG. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 108(4):549-57, 2/2004.

 

Cao Yu,  Marks JW,  Liu Z, Cheung LH, Hittelman WN, and Rosenblum MG. . Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies,  Oncogene, 33, 429-439, 2013.

 

Cao Y, Mohamedali K, Marks J, Cheung L, Hittelman W, and Rosenblum MG, Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu, Molecular Cancer Therapeutics, 12(6),979-91, 2013. This article was an MCT Highlight for the month of June and Figure 6 was selected by the Editor as cover art.

 

Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman and Michael G. Rosenblum,The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth, Molecular Cancer Therapeutics, 2013 10:2055-66. PMID: 23858102 This article was selected as an MCT Highlight for the month of July.

 

Mohamedali KA, Rosenblum MG, Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein, Biomedicines. 2017 Jul 17;5(3).

 

Cheung LH, Zhao C, Alvarez A, Hittelman W, Mohamedali W and Rosenblum, MG, Development of a human immuno-oncology therapeutic agent targeting HER2: Targeted delivery of granzyme B. J Exp Clin Cancer Res, 38(1)332, 2019.

 

Mohamedali KA, Cheung LH, Alvarez-Cienfuegos A, Hittelman WN, Rosenblum MG. Development of an  immune-oncology agent containing granzyme b targeting both VEGFR2+ tumor cells and activated tumor vasculature. Molecular Cancer Therapeutics. Submitted

 

Mohamedali KA, Aguirre B, Kejriwal N, Liu L, Chan AM, Kok SY, Duarte S,  Cheung LH, Rosenblum MG, Wadehra M. GrB-Fc-KS49, a human immuno-oncology therapeutic agent to EMP2 using a human fusion protein containing granzyme b, reshapes the tumor microenvironment by altering immune cell recruitment in breast cancer. Journal for ImmunoTherapy of Cancer. In Press. 2024.